Drug Enforcement Administration

A controlled substance is a drug or chemical whose manufacture, possession, and use are regulated by the government. The regulation takes into account factors such as medical use, potential for abuse, and safety or dependence liability. Under the Controlled Substances Act (CSA), substances are...

In a landmark case, Anthony L. Armour, a former Drug Enforcement Administration (DEA) agent, successfully challenged his termination over CBD use. Armour’s legal dispute raises critical questions about the evolving regulatory landscape surrounding cannabis and its derivatives, particularly in...

A group of 12 Democratic U.S. senators are urging the Drug Enforcement Administration this week to fully legalize cannabis. Led by Elizabeth Warren (D-Mass.) and John Fetterman (D-Penn.), the senators sent a letter signed by Senate Majority Leader Chuck Schumer (D-N.Y.), to Attorney General Merrick...

As the cannabis industry continues to blossom, it becomes increasingly important to spotlight those at the forefront of the green revolution. In this evolving landscape, visionaries are emerging, shaping the industry, societal perceptions and legal frameworks. Here are the stories and...

Dr. Sunil Aggarwal’s long-standing battle for the federal rescheduling of psilocybin for end-of-life cancer patients just hit another obstacle. What Happened: According to Marijuana Moment, the Washington-based doctor began seeking permission to provide the therapy from state and federal...

On Dec. 12, the Drug Enforcement Administration (DEA) and the Justice Department jointly released a proposed rule to place 2,5-dimethoxy-4-iodoamphetamine (DOI) and 2,5-dimethoxy-4-chloroamphetamine (DOC) in Schedule I under the federal Controlled Substances Act (CSA). Both DOI and DOC are...

Governors of Colorado, Illinois, New York, New Jersey, Maryland and Louisiana have collectively urged President Biden to reschedule cannabis to Schedule III of the Controlled Substances Act by year-end. This move, they argue, will align government policy with public opinion, where 88% of Americans...

The Drug Enforcement Administration (DEA) has proposed a considerable surplus to the originally-established 2023 production quotas of cannabinoids and psychedelics toward supporting preclinical and clinical research. This is not the first time. In late 2021 and 2022, the DEA increased the...

A recent DEA report highlighted a significant decrease in cannabis testing conducted by drug analysis laboratories, coinciding with the growing wave of marijuana legalization across the U.S. As reported by Marijuana Moment, the DEA's National Forensic Laboratory Information System (NFLIS)...

On August 29, 2023, the U.S. Department of Health and Human Services (HHS) recommended the DEA reclassify marijuana and move it from Schedule I to Schedule III, following a review by the Food and Drug Administration (FDA), as part of a process initiated by President Joe Biden in...

In a potentially game-changing decision, the Department of Health and Human Services (HHS) recently recommended the DEA to consider reclassifying cannabis from its Schedule I status — a classification that denotes no medical value, on par with substances like heroin — to...

"It's not if, it's just when," said Kim Rivers, CEO of Trulieve Cannabis Corp (OTCQX: TCNNF), regarding the recent recommendation by the Health and Human Services Department (HHS) to the Drug Enforcement Administration (DEA) regarding the rescheduling of cannabis. In a recent...

"This is a big deal," says Boris Jordan, founder and executive chairman of the board of Curaleaf Holdings, Inc. (CSE: CURA) (OTCQX: CURLF), referring to the recent recommendation by the Health and Human Services Department (HHS) to the Drug Enforcement Administration (...

"It's a watershed moment for cannabis," declared Charlie Batchell, the CEO and co-founder of Cresco Labs Inc. (CSE: CL) (OTCQX: CRLBF), during an illuminating conversation with Aaron Bry, a content producer at Benzinga. The two discussed the potentially groundbreaking reclassification...

"This is a new chapter... certainly a monumental decision, a monumental day that could lead to more significant changes," former Senator Cory Gardner (R-CO), NCR Advisory Member said in an exclusive interview with Benzinga discussing the Health and Human Services...